Main content

    Lung Cancer Clinical Trials

    CPMC Cancer Services Opens new window

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: PRIMAL STUDY: A Phase 1b/2, Randomized, Multicenter, Multinational Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined with Docetaxel (PDoc) Compared With Docetaxel (Doc) Alone in Subjects with Recurrent Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Decscription: This study is designed to assess the safety and tolerability of the combination of PEGPH20 with docetaxel (PDoc)
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with histologically confirmed and documented previously treated Stage IIIB or IV NSCLC having failed no more than 1 previous platinum-containing chemotherapy regimen
    Status: Coming soon
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study HALO-107-201

    Title: A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent
    Decscription: The purpose of this study is to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent
    Investigator: Ari Baron, MD
    Eligibility: Subjects, 18 y/o and older, with histologically or cytologically confirmed diagnosis of nonsquamous NSCLC that is Stage IIIB Stage IV, or recurrent after prior definitive intervention (radiation, surgery, or chemoradiation therapy, with or without adjuvant or neoadjuvant chemotherapy)
    Status: Active and open to enrollment
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study Incyte 266

    • updated December 2014

    Back to top